Navigation Links
IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Date:11/2/2007

ease (SD)) with duration of

response ranging from 7.2 to 29.7 months.

o To date, none of the patients who had an objective response by

RECIST have relapsed.

o The survival rate at 12 months is 67% and 18 patients are still

alive

o Progression Free Survival (PFS) from apheresis is 4.8 months

(95% CI, 3.94-5.72).

-- Assessment of pathological response in 2 patients (1 PR, 1 SD) showed

no residual melanoma.

-- Immune response: 18 out of 29 evaluated patients (62%) showed a

significant increase in TAA-specific cytokine-producing cells.

o The most frequently recognized antigens after vaccination with

UVIDEM were gp100 and MAGE.

-- UVIDEM was well tolerated with only one possibly related serious

adverse event (SAE) reported (age-related macular degeneration).

"The available results of this trial are very encouraging given the difficult-to-treat patient population," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We are confident in the potential of this product to fulfill the unmet medical need and look forward to the completion of our Phase 2 program as well as the initiation of the Phase 3 program."

About UVIDEM

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. IDM Pharma is responsible for the clinical development, regulatory and manufacturing activities for UVIDEM. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma cGMP manufacturing facilities in Irvine, California and in Paris, France.

UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase 2 clinical trials was previously announced. Thirty-eight
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
(Date:10/22/2014)... 2014   Reproductive Medicine Associates of New ... field of infertility, presents new clinical research examining ... research abstract, released during the 70 th ... in Honolulu, Hawaii , combines ... (SGD) pre-implantation genetic diagnosis (PGD). Results ...
(Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... Presented in Spine, Lung, Liver and Prostate Treatment Emphasized the Benefits of ... , ... ARAY ), a global leader in the field of radiosurgery, today ... Radiotherapy Workshop, held in Brussels, Belgium on May 28 ...
... July 6 Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today ... Board of Directors. Dr. Blutt, 53, is the Founder and Chief Executive ... that is a shareholder of Questcor. Dr. Blutt is also board-certified in ... Medical College. , , , ...
Cached Medicine Technology:Presentations at the Third European Stereotactic Radiation Therapy and Whole Body Radiotherapy Workshop Highlight Clinical Outcomes and Emerging Trends 2Presentations at the Third European Stereotactic Radiation Therapy and Whole Body Radiotherapy Workshop Highlight Clinical Outcomes and Emerging Trends 3Presentations at the Third European Stereotactic Radiation Therapy and Whole Body Radiotherapy Workshop Highlight Clinical Outcomes and Emerging Trends 4Presentations at the Third European Stereotactic Radiation Therapy and Whole Body Radiotherapy Workshop Highlight Clinical Outcomes and Emerging Trends 5Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors 2Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors 3Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors 4Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors 5
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... research suggests that testosterone replacement therapy for men with ... the prostate gland, contrary to some reports that this ... the November 15 issue of JAMA, a theme issue ... of the Urological Sciences Research Foundation and University of ...
... completely prevented the development of bone tumors in 50 ... providing early evidence that it could treat, or thwart, ... a number of cancers when they start to spread. ... D. Anderson Cancer Center reported in the journal Cancer ...
... symptoms who received a combination therapy were more likely to ... medication, according to a study in the November 15 issue ... ,Steven A. Kaplan, M.D., of Weill Cornell Medical College, ... a JAMA media briefing on men's health in New York. ...
... Family Welfare Minister has said that to shut out ... name of safety would be// against the interest of ... two day International Conclave on Traditional Medicine, which he ... society we live in today, a significant segment of ...
... been sequencing the genome of an organism called Mycobacterium-w ... complete// genome that holds promise in the treatment of ... evidence that a vaccine made from killed Mw drastically ... resistant (MDR) variety is driving this project more than ...
... medical research team looking for a cure for Duchenne Muscular ... submitted their findings// recently. ,The Stem cell Studies ... hope for those who suffer from the disease. ... genetic origin that results in muscle wasting which usually ...
Cached Medicine News:Health News:Testosterone Replacement Therapy Appears Safe for Prostate 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 3Health News:Combination Therapy More Effective for Treating Lower Urinary Tract Symptoms 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 3Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3
... drainage from the ureteropelvic junction to the ... ease of placement and patient compliance. The ... repositioning and ease of removal. AQ® is ... when activated, attracts and holds water and ...
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
Medicine Products: